Merck Nixes Some Actions in Vioxx Securities Fraud Battle
A New Jersey federal judge partially dismissed seven actions Friday within sprawling securities fraud litigation alleging Merck & Co. misrepresented the heart-attack risk of its arthritis drug Vioxx but said some...To view the full article, register now.
Already a subscriber? Click here to view full article